Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Total Non-current Liabilities
All obligations due after more than one year.
Opus Genetics, Inc.NASDAQ: IRD
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 448.1% from a year ago
Total non-current liabilities stood at $103.28M at the end of Q1 FY2026, up 448.1% from a year earlier and up 280.9% from the prior quarter.
Context
- Total non-current liabilities amounted to 154.6% of total assets at the end of Q1 FY2026, up 115.5 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +448.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27.11M USD
- Year-over-year change
- +43.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.11M | +43.9% |
| FY2024 | 2024-12-31 | 18.84M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 total non-current liabilities of $103.28M is the 3rd highest of the 10 companies compared; the peer median is $20.41M.
- Its year-over-year change of +448.1% is the highest of 9, against a peer median of -23.2%.
- Total non-current liabilities amounts to 154.6% of total assets for IRD, versus a peer median of 12.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $188.57M | -7.5% | -26.1% | 78.6% | |
| Mar 2026 | $165.2M | -47.4% | -13.5% | 88.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $103.28M | +448.1% | — | 154.6% |
| Mar 2026 | $85.01M | -0.4% | -0.4% | 42.4% | |
| Mar 2026 | $71.78M | -12.9% | -33.4% | 61.0% | |
| Mar 2026 | $20.41M | -11.5% | -9.4% | 7.5% | |
| Mar 2026 | $16.92M | -42.9% | — | 12.7% | |
| Mar 2026 | $5.79M | -33.5% | -39.3% | 11.6% | |
| Mar 2026 | $447.99K | — | +189.2% | 1.5% | |
| Mar 2026 | $176K | -37.1% | -56.6% | 0.5% | |
| Peer median (excluding IRD) | $20.41M | -23.2% | -19.8% | 12.7% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.